


## Salvianolic acid B

<b>Cat. No.:</b>	HY-N1362
<b>CAS No.:</b>	121521-90-2
<b>Molecular Formula:</b>	C <sub>36</sub> H <sub>30</sub> O <sub>16</sub>
<b>Molecular Weight:</b>	718.61
<b>Target:</b>	Autophagy
<b>Pathway:</b>	Autophagy
<b>Storage:</b>	Powder    -20°C    3 years 4°C        2 years



\* The compound is unstable in solutions, freshly prepared is recommended.

### SOLVENT & SOLUBILITY

#### In Vitro

H<sub>2</sub>O : 50 mg/mL (69.58 mM; ultrasonic and adjust pH to 3 with HCl)  
DMSO : 25 mg/mL (34.79 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	1.3916 mL	6.9579 mL	13.9158 mL
5 mM	0.2783 mL	1.3916 mL	2.7832 mL
10 mM	0.1392 mL	0.6958 mL	1.3916 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: PBS  
Solubility: 50 mg/mL (69.58 mM); Clear solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 2.5 mg/mL (3.48 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 2.5 mg/mL (3.48 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 2.5 mg/mL (3.48 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

Salvianolic acid B is an active ingredient of *Salvia miltiorrhiza*, which has been widely applied in China for the management of various microcirculation-related disorders, such as cardiovascular disease, cerebrovascular disease, and diabetic vascular complication.

#### In Vitro

Salvianolic acid B (SA-B) 1 and 10 micromol/L decrease the cell active TGF-beta1 secretion by 63.3 % and 15.6 % of the

control, down-regulate pro-collagen alpha1(I) mRNA expression to 77.0% and 51.8% respectively (P<0.05). SA-B 1 and 10 micromol/L also inhibit MAPK activity by 1 to 2 fold respectively.<sup>[3]</sup>

The degradation of Salvianolic acid B is temperature dependent. It was stable at 4°C for 30 h in aqueous solution. However, decomposition of Salvianolic acid B aqueous solution occurs automatically at 25°C, and is enhanced at 37, 65 and 100°C. On the other hand, Salvianolic acid B is also stable at 4, 25 and 37°C for 30 h in TPA (total phenolic acids).<sup>[4]</sup>

Salvianolic acid B is stable for 30 h in buffered phosphate aqueous solutions at pH 1.5, 3.0 and 5.0. With an increase of pH from the neutral, the stability of Sal B decreased.<sup>[4]</sup>

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### In Vivo

Salvianolic acid B (SalB) (5 mg · kg<sup>-1</sup> · h<sup>-1</sup>) significantly attenuates LPS-induced pulmonary microcirculatory disturbance, including the increase in leukocyte adhesion and albumin leakage. In addition, LPS increases pulmonary tissue wet-to-dry weight ratio and tumor necrosis factor [alpha] and interleukin 8 levels in plasma and bronchoalveolar lavage fluid enhances the expression of E-selectin, intercellular adhesion molecule 1, myeloperoxidase, MMP-2, and MMP-9, whereas it decreases the expression of AQP-1 and AQP-5 in pulmonary tissue, all of which are attenuated by SalB pretreatment<sup>[1]</sup>. SalB administration (10 mg/kg) significantly ameliorate the Aβ25-35 peptide-induced memory impairment in the passive avoidance task (P<0.05). SalB treatment also reduced the number of activated microglia and astrocytes that are observed during the inflammatory reaction after the administration of the Aβ25-35 peptide. Moreover, SalB markedly reduce inducible nitric oxide synthase and cyclooxygenase-2 expression levels and thiobarbituric acid reactive substances, which are increased by the administration of the Aβ25-35 peptide. Furthermore, SalB administration significantly rescue the Aβ25-35 peptide-induced decrease of choline acetyltransferase and brain-derived neurotrophic factor protein levels<sup>[2]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## CUSTOMER VALIDATION

- Phytomedicine. 2019 May;58:152754.
- Bioengineered. 2022 Feb;13(2):3486-3502.
- Pharmaceuticals. 2022, 15(2), 179.
- Biochem Biophys Res Commun. 2020 Jun 4;526(3):733-737.
- Biologia Futura. 2022.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Antaris AL, et al. A small-molecule dye for NIR-II imaging. Nat Mater. 2016 Feb;15(2):235-42.

[2]. Antaris AL, et al. A small-molecule dye for NIR-II imaging. Nat Mater. 2016 Feb;15(2):235-42.

[3]. Antaris AL, et al. A small-molecule dye for NIR-II imaging. Nat Mater. 2016 Feb;15(2):235-42.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA